Literature DB >> 31009228

Salinomycin-Loaded Gold Nanoparticles for Treating Cancer Stem Cells by Ferroptosis-Induced Cell Death.

Yongmei Zhao1, Wei Zhao2, Yi Chieh Lim3, Tianqing Liu4.   

Abstract

Cancer stem cells (CSCs) are a subpopulation of tumor cells that exhibit self-renewal, differentiation, and tumorigenicity. CSCs are highly resistant to the conventional cancer treatment and have been associated with metastasis. Several studies have been shown that salinomycin (Sal) has the potential to target cancer stem cells evidenced by in vitro and in vivo tumor models. Here, salinomycin was conjugated with biocompatible gold nanoparticles (AuNPs) coated with poly(ethylene glycol) to improve its specificity in targeting breast cancer stem cells (BCSCs). BCSCs derived from CD24low/CD44high subpopulation showed high sensitivity to Sal-AuNP treatment. An in-depth analysis on the mechanism of action of Sal-AuNPs indicated ferroptosis, an iron-dependent cell death, was achieved as a result of iron accumulation and inhibition of antioxidant properties. This also led to the induction of oxidative stress, mitochondrial dysfunction, and lipid oxidation. Our findings suggest Sal-AuNP treatment is an efficient therapeutic avenue in eliminating cancer stem cells.

Entities:  

Keywords:  ROS; cancer stem cells; ferroptosis; gold nanoparticles; salinomycin

Mesh:

Substances:

Year:  2019        PMID: 31009228     DOI: 10.1021/acs.molpharmaceut.9b00132

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  15 in total

Review 1.  Processing body (P-body) and its mediators in cancer.

Authors:  Bernard Nsengimana; Faiz Ali Khan; Ebenezeri Erasto Ngowi; Xuefeng Zhou; Yu Jin; Yuting Jia; Wenqiang Wei; Shaoping Ji
Journal:  Mol Cell Biochem       Date:  2022-01-28       Impact factor: 3.396

Review 2.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675

Review 3.  The interaction between ferroptosis and lipid metabolism in cancer.

Authors:  Dingshan Li; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2020-06-30

Review 4.  Emerging agents that target signaling pathways in cancer stem cells.

Authors:  Yue Yang; Xiaoman Li; Ting Wang; Qianqian Guo; Tao Xi; Lufeng Zheng
Journal:  J Hematol Oncol       Date:  2020-05-26       Impact factor: 17.388

5.  Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer.

Authors:  Guanchen Zhu; Kaikai Wang; Haixiang Qin; Xiaozhi Zhao; Wei Chen; Linfeng Xu; Wenmin Cao; Hongqian Guo
Journal:  J Nanobiotechnology       Date:  2020-09-04       Impact factor: 10.435

6.  Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer.

Authors:  Mangmang Sang; Renjie Luo; Yidan Bai; Jun Dou; Zhongtao Zhang; Fulei Liu; Feng Feng; Jian Xu; Wenyuan Liu
Journal:  Theranostics       Date:  2019-08-14       Impact factor: 11.556

Review 7.  Ferroptosis: Final destination for cancer?

Authors:  Zeng Ye; Wensheng Liu; Qifeng Zhuo; Qiangsheng Hu; Mengqi Liu; Qiqing Sun; Zheng Zhang; Guixiong Fan; Wenyan Xu; Shunrong Ji; Xianjun Yu; Yi Qin; Xiaowu Xu
Journal:  Cell Prolif       Date:  2020-02-25       Impact factor: 6.831

Review 8.  Ferroptosis: mechanisms and links with diseases.

Authors:  Hong-Fa Yan; Ting Zou; Qing-Zhang Tuo; Shuo Xu; Hua Li; Abdel Ali Belaidi; Peng Lei
Journal:  Signal Transduct Target Ther       Date:  2021-02-03

9.  Synergistic inhibition of the growth of MDA-MB-231 cells in triple-negative breast cancer by salinomycin combined with 17-AAG and its mechanism.

Authors:  Duo He; Bo Wu; Juan Du; Ling Li; Jumei Zhao
Journal:  Oncol Lett       Date:  2022-03-01       Impact factor: 2.967

Review 10.  Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases.

Authors:  J P Jose Merlin; Xiaogang Li
Journal:  Front Genet       Date:  2022-01-05       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.